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Background
Amyotrophic lateral sclerosis (ALS) is a progressive, paralytic 
disorder characterized by degeneration of motor neurons in the brain 
and spinal cord. Common feature in cases of both familial and 
sporadic ALS is aggregation of cytoplasmic proteins, prominently but 
not exclusively in motor neurons. One of the well-characterized 
animal models in our lab is expressing an ALS related mutation, 
C71G, in Profilin (PFN1), a recognized actin-binding protein. 
Mutations in the pfn1 gene were previously shown to result in protein 
aggregation and insolubility of PFN1 in mouse ALS model; however, 
the impact and mechanism of PFN1 aggregation remain not well 
understood. 
Post-Translational modification (PTMs) of neural proteins is one of 
the frequent observations in most neurodegenerative conditions 
related to protein aggregation. I hypothesize that under-characterized 
PFN1 protein post-translational modification, such as 
phosphorylation, contributes to the pathogenesis of ALS by 
accelerating PFN1 aggregation. 
1. pPFN1 antibody marks a pathology specific 
aggregate pattern in ALS mice model white matter
Paraffin embedded 
Lumbar spinal cord  
sections from PFN1 
WT and non-transgenic 
animals co-stained with 
pPFN1 antibody and 
hematoxylin post 
antigen retrieval show a 
gradual increase of 
pPFN1 intense staining 
in white matter. 
2. pPFN1 aggregates are found in the white matter
Profilin1 protein structure and ALS-linked mutations
4. Endogenous pPFN1/PFN1 is found in both soluble 
and insoluble fractions in PFN1C71G
A. Endogenous pPFN1 aggregates differentially found in PFN1C71G white matter. 
Mouse spinal cord sections were stained for pPFN1 and Neurofilament-L antibodies and 
visualized with confocal microscopy. (scale bar = 20 um) 
B. Mutant PFN1 aggregates double positive for V5 and pPFN1 found in spinal cord 
white matter and show a distinctive morphology. (scale bar=10um) C. Double staining 
with GFAP and pPFN1 antibodies confirms the abundant presence of PFN1 
phosphorylation in astrocytes. D. Some aggregates are colocalized with DNA-damaged 
cells. E. Few of aggregates are colocalized with neutrophils positive for Gr-1(scale 
bar=10um)
A. Schematic showing the summary of protocol used for fractionation of brainstem tissue 
explained in detail in material methods section.
B. Representative blot of age matched nTg, PFN1 WT and PFN1 C71G (paralyzed) showing 
the PFN1 and its phosphorylation in the soluble (S1), Triton-x100(S2), sarcosyl(S3) and 
Urea/SDS(S4) fractions respectively. The total protein stain is indicating the amount of total 
fluorescent protein present in each lane. 
5. pPFN1 also marks aggregates in mutant SOD1 ALS 
model
A. Double staining with pPFN1 and misfolded SOD1 antibody. pPFN1 is partially overlapping 
with SOD1 positive aggregates marked with arrowheads (Scale bar=20um). All panels are 
same magnification and obtained after maximum projection of pPFN1 staining across z-stacks 
in white matter.
B. Brainstem biochemical fractionation of nTg matched with a paralyzed mouse showing the 
presence of endogenous pfn1 aggregation in SOD1 G93A mice in Urea/SDS fraction. Soluble 
(S1), Triton-x100(S2), sarcosyl(S3) and Urea/SDS(S4) 
A. Double staining with pPFN1 and PLP1 myelin marker 
B. Increased Ppfn1 in PLP1+ S100B+ cells
C. Double staining with pPFN1 and Iba1. pPFN1 signal does not overlap with the Iba1 
signal (arrowhead) (Scale bar=20um)
D. CD68 positive glial cells often found in proximity of pPFN1 positive areas but do not 
colocalize with pPFN1 signal. Arrowhead indicate an aggregate positive area that is 
engulfed by a CD68 positive cell (Scale bar=20um). E. The magnified panel in the right 
establishes the relationship of a pPFN1 stain positive area with CD68 expressing cells from 
two different angles in a confocal 3D reconstruction image (Scale bar=10um). 
3. pPFN1 marked myelin colocalized aggregates 
interacting with microglia in the white matter 
6. Both PFN1 and its phosphorylation is present in 
insoluble fraction of human sporadic ALS cases
Biochemical fractionation of spinal cord postmortem frozen samples to Soluble (S1), Triton-
x100 (S2) and Urea/SDS (S4) fractions respectively. Sarcosyl soluble (S3) fraction has not 
been shown for simplicity since signal was below detection in this fraction.
Conclusion
pPFN1 antibody marks phosphorylation of PFN1 which can be found 
in aggregates. White matter pathology resulting from potentially 
endogenously expressed PFN1 phosphorylation in both ALS mice models 
independent of mutation type. Overall, our results suggest for the first time a role 
for phosphorylation of PFN1 in protein aggregation and white matter pathology in 
ALS that will shed more light on the mechanism of disease and developing 
potential therapeutics in near future
A. pPFN1 antibody recognizes IPed PFN1 in 
soluble fraction
Western blot using pPFN1 and PFN1 
antibodies on the whole-cell extract of NSC-
34 cells transfected with PFN1wt (WT) and 
PFN1C71G (C71G) constructs exposed to 
immunoprecipitation using V5 antibody 
(marking exogenously expressed PFN1). 
Mouse IgG (I) and lysate transfected with an 
empty plasmid (M) were used as controls. 
Mutant is marked with small arrow and 
endogenous protein is marked with 
arrowhead.
B. pPFN1 staining with peptide absorption. 
Lumbar spinal cord section stained with the 
pPFN1 antibody with and without the 
presence of its commercial blocking peptide 
is shown. A PFN1C71G symptomatic stage 
section is compared to an age matched 
PFN1wt (scale bar=20um) 
C. Specificity of pPFN1 in 
immunofluorescence staining on NSC34 cells 
expressing phospho mutant(S138A) and 
phospho mimics (S138D) PFN1 constructs 
visualized with confocal microscopy. pPFN1 
signal is increased in presence of mutant 
PFN1 and its phosphomimic but not in 
phosphomutant condition (scale bar=5um)
D. A PFNWT expressing mice spinal cord 
section treated with lambda phosphatase for 
1hr compared to a non-treated control
E. PFN1 and pPFN1 antibodies validation on 
a conditional PFN1 knockout spinal cord 
protein lysate
pPFN1 antibody selectively reacts with phosphorylated PFN1
